SCHEMBL6722155

SCHEMBL6722155

NCC1CC(CCCC(=O)O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.44
GABRR1 P24046 5/20 0.44
THRB P10828 2/20 0.44
BLM P54132 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 2/20 0.44
GABRR2 P28476 2/20 0.44
GABRR3 A8MPY1 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
HDAC3 O15379 1/20 0.44
GABBR2 O75899 1/20 0.44
CYP1A2 P05177 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
SLC6A1 P30531 1/20 0.44
GABRA5 P31644 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186141 0.80 KDM5A (0.45) LMNAGABRR1THRBBLMKMT2A
Adipic Acid SCHEMBL5712299 0.78 NFKB1 (0.46) LMNAGABRR1THRBBLMKMT2A
SCHEMBL1661621 0.76 KDM5A (0.56) LMNAGABRR1THRBBLMKMT2A
Adipic Acid SCHEMBL11871671 0.76 LMNA (0.58) LMNAGABRR1THRBBLMKMT2A
SCHEMBL1421999 0.75 LMNA (0.47) LMNAGABRR1THRBBLMKMT2A
SCHEMBL4612433 0.75
SCHEMBL29193847 0.75 KDM5A (0.53) LMNAGABRR1THRBBLMKMT2A
SCHEMBL23495089 0.74 LMNA (0.44) LMNAKMT2ATSHRHDAC3SLC6A12
SCHEMBL21085092 0.73 ALOX5 (0.42) LMNAGABRR1THRBBLMKMT2A
SCHEMBL19650816 0.73 SLC6A12 (0.46) LMNAGABRR1GABRR2GABRA1SLC6A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198820-A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity XENOPORT, INC. 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198820-A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity GABRB1, GABRB2, GABRB3 LMNA 3884/4885GABRR1 25/4885THRB 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.